Duke University spin-out Aerie Pharmaceuticals files with the SEC for initial public offering.
Aerie Pharmaceuticals, a life sciences firm specialising in tackling eye diseases, has filed for its initial public offering (IPO) with a fundraising target of $57.5m. The US-based biotech, founded in 2005, is commercialising research from Duke University into ophthalmic disease. Its main product, a treatment for glaucoma, is currently wrapping up Phase II trials with…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
